UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.040

Sortiert nach

102 Obésité sévère et fonction respiratoire

Revue des maladies respiratoires, 2004, Vol.21, p.49-49

2004

Volltextzugriff (PDF)

1081 Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC): A phase I/II study

European journal of cancer (1990), 1995-11, Vol.31, p.S225-S225

1995

Volltextzugriff (PDF)

109P Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S757-S758

2021

Volltextzugriff (PDF)

109P Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC) after discontinuing an immune checkpoint inhibitor (ICI) therapy in second-line or later in Germany and France

Annals of oncology, 2021-12, Vol.32, p.S1422-S1423

2021

Volltextzugriff (PDF)

110P Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S758-S758

2021

Volltextzugriff (PDF)

110TiPA phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Volltextzugriff (PDF)

1142PDEfficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

116OHealth-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

12 Étude IFCT0401-bio : analyses anatomopathologique et de la voie de signalisation du récepteur du facteur de croissance épidermique (EGFR) dans les adénocarcinomes pulmonaires de type bronchiolo-alvéolaire (ADC-CBA) non résécables traités par gefitinib

Revue des maladies respiratoires, 2007, Vol.24, p.12-12

2007

Volltextzugriff (PDF)

1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib

Annals of oncology, 2021-09, Vol.32, p.S958-S958

2021

Volltextzugriff (PDF)

1219 - Cost-Utility Analysis of Maintenance Therapy with Either Gemcitabine or Erlotinib versus Observation with Predefined Second-Line Treatment after Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Nsclc: Ifct-Gfpc 0502-ECO Phase III Study

Annals of oncology, 2012-09, Vol.23, p.ix397-ix398

2012

Volltextzugriff (PDF)

1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Annals of oncology, 2020-09, Vol.31, p.S805-S806

2020

Volltextzugriff (PDF)

125 The high pharmacokinetic variability of adriamycin, etoposide and ifosfamide among small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 1997-08, Vol.18, p.34-35

1997

Volltextzugriff (PDF)

1258P MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study

Annals of oncology, 2021-09, Vol.32, p.S987-S987

2021

Volltextzugriff (PDF)

1266PQUALITY OF LIFE (QOL) RESULTS FROM THE PHASE 3 REVEL STUDY OF RAMUCIRUMAB + DOCETAXEL (RAM + DTX) VERSUS PLACEBO + DOCETAXEL (PL + DTX) IN ADVANCED/METASTATIC NSCLC PATIENTS (PTS) WITH PROGRESSION AFTER PLATINUM BASED CHEMOTHERAPY

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv445-iv445

2014

Volltextzugriff (PDF)

128 Preliminary results of a phase II study with Taxol ® (paclitaxel) and cisplatin in advanced non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 1997-08, Vol.18, p.35-36

1997

Volltextzugriff (PDF)

1287PRETROSPECTIVE MULTICENTER STUDY IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION TREATED FIRST-LINE TYROSINE KINASE INHIBITOR (TKI): EVALUATION OF PROGRESSION ACCORDING TO RECIST, THERAPEUTIC APPROACH AND ITS EFFECT

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv453-iv453

2014

Volltextzugriff (PDF)

1305P Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L

Annals of oncology, 2020-09, Vol.31, p.S844-S844

2020

Volltextzugriff (PDF)

1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

Annals of oncology, 2023-10, Vol.34, p.S762-S763

2023

Volltextzugriff (PDF)

1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)

Annals of oncology, 2020-09, Vol.31, p.S854-S855

2020

Volltextzugriff (PDF)

1334TiPRANDOMISED, MULTICENTRE, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VS CRIZOTINIB IN TREATMENT-NAïVE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NSCLC (ALEX STUDY)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv469-iv470

2014

Volltextzugriff (PDF)

1345PData-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)

Annals of oncology, 2021-09, Vol.32, p.S1026-S1026

2021

Volltextzugriff (PDF)

1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)

Annals of oncology, 2020-09, Vol.31, p.S866-S866

2020

Volltextzugriff (PDF)

1 – 25 von 1.040

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(766)
Mit Volltextzugriff
(683)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(304)
Science & Technology
(167)
Life Sciences & Biomedicine
(161)
Female
(155)
Male
(150)
Adult
(125)
Middle Aged
(119)
Aged
(96)
Sciences Biologiques Et Medicales
(94)
Sciences Medicales
(92)
Oncology
(89)
Biological And Medical Sciences
(55)
Medical Sciences
(49)
Life Sciences
(47)
Lung Neoplasms - Drug Therapy
(47)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(42)
Chemotherapy
(40)
Pneumologie
(38)
Adolescent
(33)
Respiratory System
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

102 Obésité sévère et fonction respiratoire

1081 Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC): A phase I/II study

109P Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

109P Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC) after discontinuing an immune checkpoint inhibitor (ICI) therapy in second-line or later in Germany and France

110P Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France

110TiPA phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions

1142PDEfficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort

116OHealth-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study

1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDClung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)

12 Étude IFCT0401-bio : analyses anatomopathologique et de la voie de signalisation du récepteur du facteur de croissance épidermique (EGFR) dans les adénocarcinomes pulmonaires de type bronchiolo-alvéolaire (ADC-CBA) non résécables traités par gefitinib

1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib

1219 - Cost-Utility Analysis of Maintenance Therapy with Either Gemcitabine or Erlotinib versus Observation with Predefined Second-Line Treatment after Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Nsclc: Ifct-Gfpc 0502-ECO Phase III Study

1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

125 The high pharmacokinetic variability of adriamycin, etoposide and ifosfamide among small cell lung cancer patients

1258P MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study

1266PQUALITY OF LIFE (QOL) RESULTS FROM THE PHASE 3 REVEL STUDY OF RAMUCIRUMAB + DOCETAXEL (RAM + DTX) VERSUS PLACEBO + DOCETAXEL (PL + DTX) IN ADVANCED/METASTATIC NSCLC PATIENTS (PTS) WITH PROGRESSION AFTER PLATINUM BASED CHEMOTHERAPY

128 Preliminary results of a phase II study with Taxol ® (paclitaxel) and cisplatin in advanced non-small cell lung cancer (NSCLC)

1287PRETROSPECTIVE MULTICENTER STUDY IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION TREATED FIRST-LINE TYROSINE KINASE INHIBITOR (TKI): EVALUATION OF PROGRESSION ACCORDING TO RECIST, THERAPEUTIC APPROACH AND ITS EFFECT

1305P Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L

1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)

1334TiPRANDOMISED, MULTICENTRE, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VS CRIZOTINIB IN TREATMENT-NAïVE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NSCLC (ALEX STUDY)

1345PData-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center

1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)

1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)

Suchergebnisse filtern